Citi Downgrades Esperion Therapeutics (ESPR) to Neutral

November 14, 2016 8:17 AM EST
Get Alerts ESPR Hot Sheet
Price: $11.50 --0%

Rating Summary:
    5 Buy, 6 Hold, 1 Sell

Rating Trend: Up Up

Today's Overall Ratings:
    Up: 8 | Down: 4 | New: 1
Trade ESPR Now!
Join SI Premium – FREE

Get daily under-the-radar research with StreetInsider.com's Stealth Growth Insider Get your 2-Wk Free Trial here.

Citi downgraded Esperion Therapeutics (NASDAQ: ESPR) from Buy to Neutral.

For an analyst ratings summary and ratings history on Esperion Therapeutics click here. For more ratings news on Esperion Therapeutics click here.

Shares of Esperion Therapeutics closed at $11.99 yesterday.



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In






Related Categories

Downgrades

Related Entities

Citi

Add Your Comment